Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival (OS) in people with previously untreated BRAF V600 mutation-positive metastatic melanoma, compared to chemotherapy. End Quote

(1888PressRelease) June 07, 2011 - In the study, the risk of death was reduced by 63 percent for people who received vemurafenib compared to those who received chemotherapy (hazard ratio [HR]=0.37, p

###

space

Other Related Press Releases

China Smart Grid PLC Industry Report, 2010-2011-Published by ResearchInChina by Researchinchina
DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak by Business Updates
CIO magazine Honors Life Technologies for Leadership in Information Technology by Business Updates
Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations by Financial News
Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer by Financial News